Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News GeoVax Labs Inc GOVX

Healthcare Biotechnology
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan... see more

Recent & Breaking News (NDAQ:GOVX)

GeoVax Highlights 2026 as a Pivotal Year for Progress

TheNewsWire January 20, 2026

GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement

TheNewsWire January 8, 2026

GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week

TheNewsWire January 6, 2026

GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering

TheNewsWire December 19, 2025

GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine

TheNewsWire December 18, 2025

GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA

TheNewsWire December 18, 2025

GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026

TheNewsWire December 17, 2025

GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design

TheNewsWire December 16, 2025

GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients

TheNewsWire December 15, 2025

GeoVax Addresses Identification of New Mpox Variant

TheNewsWire December 11, 2025

GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory Board

TheNewsWire December 10, 2025

GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy

TheNewsWire December 9, 2025

GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck Cancer

TheNewsWire December 8, 2025

GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference

TheNewsWire November 24, 2025

GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update

TheNewsWire November 13, 2025

GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination

TheNewsWire November 10, 2025

GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025

TheNewsWire November 4, 2025

GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement

TheNewsWire November 3, 2025

BIO CEO Warns U.S. Could Lose Biotech Leadership Within Two Years; GeoVax Calls on Congress and Administration to Act Now

TheNewsWire October 30, 2025

GeoVax Connects IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients With Recent Clinical Data for GEO-CM04S1

TheNewsWire October 29, 2025

Podcasts